Silver Book Fact

For beneficiaries with wet age-related macular degeneration (AMD), annual Medicare part B payments for vision care increased from $1,504 per beneficiary in 1994 to $3,263 in 2006–due in large part to anti-VEGF treatments.

Day S, Acquah K, Lee P, Mruthyunjaya P, et al. Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994-2007. Ophthalmol. 2011; 152(6): 1014-20. http://www.ajo.com/article/S0002-9394%2811%2900410-7/abstract

Reference

Title
Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994-2007
Publication
Ophthalmol
Publication Date
2011
Authors
Day S, Acquah K, Lee P, Mruthyunjaya P, et al.
Volume & Issue
Volume 152, Issue 6
Pages
1014-20
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • Americans 65+ that have severe visual impairment
    6.5 million Americans over the age of 65 have severe visual impairment that threatens to limit their mobility, independence, and quality of life.  
  • In one study, individuals age 80 and older made up 8% of the population, yet accounted for 69% of cases of blindness.  
  • It is estimated that those aged 50 years or older with macular degeneration will double– 9 million to 18 million– by 2050.  
  • One study reported emotional distress scores in age-related macular degeneration (AMD) patients comparable to scores of individuals with serious illnesses such as melanoma and HIV.  
  • Age-related eye diseases are the primary causes of vision impairment and blindness in the U.S.